Health

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'

SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pha...

2023-03-17 21:00 3561

RVAC Medicines announces research collaboration with University of Pennsylvania mRNA Vaccine Pioneer

BOSTON, March 17, 2023 /PRNewswire/ -- RVAC Medicines (US), Inc., a messenger RNA (mRNA) technology company with its global headquarters inSingapore, today announced the collaboration under a Sponsored Research Agreement with the University of Pennsylvania ("Penn") focused on the discovery and dev...

2023-03-17 21:00 3802

Samsung Biologics announces construction of Plant 5 to commence Bio Campus II capacity expansion

* The company plans to begin construction in the first half of 2023 and commence operations in 2025 * As part of Samsung Biologics' second Bio Campus, Plant 5 will hold a manufacturing capacity of 180,000 liters, expanding the company's total site capacity to 784,000 liters upon its completio...

2023-03-17 19:25 3014

Sisram Medical Ltd. to Announce Full Year 2022 Financial Results on March 21, 2023

Conference call to be held on March 22, 2023, at 8:00 a.m. Eastern Time HONG KONG, March 17, 2023 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram",stock code: 1696.HK; together with its subsidiaries referred as the "Group"), a global consumer wellness group featuring a first-of-its-k...

2023-03-17 19:04 4529

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results

BEIJING, March 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the fourth quarter and fiscal yea...

2023-03-17 18:43 4797

WATERDROP ANNOUNCES CERTAIN BOARD AND EXECUTIVE CHANGES

BEIJING, March 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced the appointment of Mr.Wei Ran as a new director to its board of direc...

2023-03-17 18:35 3737

SYMBYX announces promising Sydney Adventist Hospital clinical trial results for Parkinson's using the SYMBYX Neuro - a new light therapy wellness helmet

SYDNEY, March 17, 2023 /PRNewswire/ -- SYMBYX, an Australian medtech company developing light therapies for intractable disease conditions, today announced the results of a Sydney Adventist Hospital (commonly known as the San) triple-blinded, randomised controlled trial investigating the effects ...

2023-03-17 18:30 2059

China's first personalized neoantigen-targeted cancer vaccine receives NMPA's clinical trial approval

BEIJING, March 17, 2023 /PRNewswire/ -- According the latest data released at the Clinical Trials Implied Approval section on the website ofChina's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Likang Life Sciences (hereinafter referred to as "Likang") h...

2023-03-17 14:56 1961

UnionTech Showcases Dental 3D Printer S300+ at IDS 2023, International Dental Show in Cologne, Germany

COLOGNE, Germany, March 16, 2023 /PRNewswire/ -- The biennial International Dental Show, will take place inCologne, Germany from March 14 to 18, 2023. The five-day exhibition will showcase the latest products, developments, and trends in the dental industry. Uniontech, a leading provider of digi...

2023-03-17 10:34 1755

GCCL Develops PBMC Resource Management System

To enhance accuracy and credibility of sample management and provide real-time information for customers YONGIN, South Korea, March 16, 2023 /PRNewswire/ -- GCCL (Global Clinical Central Lab), a company specializes in clinical trial sample analysis, announced onMar. 17 that it has built a resour...

2023-03-17 09:26 1603

AXA Study: 1 out of 5 people in Hong Kong feel they are flourishing

Employees working for companies which actively promote workplace wellbeing are 3.5 times more likely to flourish HONG KONG, March 16, 2023 /PRNewswire/ -- AXA Hong Kong and Macau ("AXA") today announced the findings of the annual AXA Study of Mind Health and Wellbeing 2023 (the Study) which...

2023-03-17 09:12 2839

YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ

YS Biopharma Ordinary Shares and Warrants to Trade on the Nasdaq Under Tickers "YS" and "YSBPW" NEW YORK, March 17, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (the "Company" or "YS Biopharma"), a global biopharmaceutical company focusing on new generations of vaccines and therapeutic biologic...

2023-03-17 04:30 2430

Oral Care Brand Bitvae Celebrates World Oral Health Day With a Collection of High-Quality, Easy-to-Use Products Accessible to All

The oral care brand joins dentists, professionals and individuals around the world to raise awareness of the importance of maintaining good oral health at every stage of life. NEW YORK, March 16, 2023 /PRNewswire/ -- Bitvae

2023-03-16 22:20 2178

Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients

SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-co...

2023-03-16 21:00 1787

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application (sNDA) for Illuccix® (kit for the preparation of gallium Ga 68 goze...

2023-03-16 20:28 1831

Angel Yeast Showcases Latest Product Innovations at Food Ingredients China 2023

SHANGHAI, March 16, 2023 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, has come to Food Ingredients China 2023,Asia's premier trade show in the food additives and ingredients industry, to display its newest yeast innovations. Angel'...

2023-03-16 20:16 3815

TurtleTree debuts first-ever animal-free lactoferrin—one of milk’s most valuable and functional proteins—in world-first tasting

Known affectionately as "pink gold," TurtleTree premiers its highly-prized, health-boosting, pink-hued protein—LF+—in an exclusive tasting before 2023 market entry. WOODLAND, Calif., March 16, 2023 /PRNewswire/ -- TurtleTree, a global leader in animal-free functional dairy proteins, will to...

2023-03-16 20:00 2547

Bolstering Healthcare Quality in Malaysia with Renowned Flagship Hospitals

Malaysia's position as a safe and trusted destination for high-quality healthcare services is reinforced with the debut of flagship medical tourism hospitals in the country. KUALA LUMPUR, Malaysia, March 16, 2023 /PRNewswire/ -- Malaysia has debuted its first-of-its-kind Flagship Medical Tourism...

2023-03-16 16:12 4630

The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib(ABSK021)was granted BTD by FDA and CDE, discovered and developed byChina biotech。 SHANGHAI, March 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256. HK, referred to as "Abbis...

2023-03-16 10:00 3258

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...

2023-03-16 09:58 2352
1 ... 255256257258259260261 ... 848